118 related articles for article (PubMed ID: 28607601)
1. Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development.
Berry JS; Vreeland TJ; Hale DF; Jackson DO; Trappey AF; Greene JM; Hardin MO; Herbert GS; Clifton GT; Peoples GE
J Cancer; 2017; 8(7):1255-1262. PubMed ID: 28607601
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.
Vreeland TJ; Litton JK; Qiao N; Philips AV; Alatrash G; Hale DF; Jackson DO; Peace KM; Greene JM; Berry JS; Clifton GT; Peoples GE; Mittendorf EA
Clin Immunol; 2018 Jul; 192():6-13. PubMed ID: 29574039
[TBL] [Abstract][Full Text] [Related]
3. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Brown TA; Byrd K; Vreeland TJ; Clifton GT; Jackson DO; Hale DF; Herbert GS; Myers JW; Greene JM; Berry JS; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwel GL; Peoples GE
Cancer Med; 2019 Aug; 8(10):4678-4687. PubMed ID: 31274231
[TBL] [Abstract][Full Text] [Related]
4. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients.
Kim DK; Lee TV; Castilleja A; Anderson BW; Peoples GE; Kudelka AP; Murray JL; Sittisomwong T; Wharton JT; Kim JW; Ioannides CG
Anticancer Res; 1999; 19(4B):2907-16. PubMed ID: 10652572
[TBL] [Abstract][Full Text] [Related]
5. The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor.
Kim DK; Kim JH; Kim YT; Kim JW; Ioannides CG
Yonsei Med J; 2002 Dec; 43(6):691-700. PubMed ID: 12497651
[TBL] [Abstract][Full Text] [Related]
6. Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
Jackson DO; Byrd K; Vreeland TJ; Hale DF; Herbert GS; Greene JM; Schneble EJ; Berry JS; Trappey AF; Clifton GT; Hardin MO; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwell GL; Peoples GE
Oncotarget; 2017 Feb; 8(9):15912-15923. PubMed ID: 27852036
[TBL] [Abstract][Full Text] [Related]
7. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
[TBL] [Abstract][Full Text] [Related]
8. Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53.
Chhabra A; Mukherji B; Batra D
Expert Opin Ther Targets; 2017 Feb; 21(2):117-129. PubMed ID: 27935327
[TBL] [Abstract][Full Text] [Related]
9. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro.
Van Waes C; Monach PA; Urban JL; Wortzel RD; Schreiber H
Tissue Antigens; 1996 May; 47(5):399-407. PubMed ID: 8795140
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
Cormier JN; Salgaller ML; Prevette T; Barracchini KC; Rivoltini L; Restifo NP; Rosenberg SA; Marincola FM
Cancer J Sci Am; 1997; 3(1):37-44. PubMed ID: 9072306
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
12. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
13. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
Rice J; Elliott T; Buchan S; Stevenson FK
J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
[TBL] [Abstract][Full Text] [Related]
14. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
Bristol JA; Schlom J; Abrams SI
J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of c-Jun N-terminal kinase rescues influenza epitope-specific human cytolytic T lymphocytes from activation-induced cell death.
Mehrotra S; Chhabra A; Hegde U; Chakraborty NG; Mukherji B
J Leukoc Biol; 2007 Feb; 81(2):539-47. PubMed ID: 17062604
[TBL] [Abstract][Full Text] [Related]
16. Vaccine Trials for the Clinician: Prospects for Tumor Antigens.
Osanto S
Oncologist; 1997; 2(5):284-299. PubMed ID: 10388061
[TBL] [Abstract][Full Text] [Related]
17. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
18. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
[TBL] [Abstract][Full Text] [Related]
19. Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor.
Chhabra A; Mehrotra S; Chakraborty NG; Dorsky DI; Mukherji B
Eur J Immunol; 2006 Dec; 36(12):3167-74. PubMed ID: 17109472
[TBL] [Abstract][Full Text] [Related]
20. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
